Cargando…

A review of prospective Clinical Trials for neurogenic bladder: Pharmaceuticals

INTRODUCTION: The neurogenic urinary bladder is defined as a dysfunctional bladder associated with a known neurological injury. We review the data from good quality clinical trials looking at drug therapy for the neurogenic bladder. MATERIALS AND METHODS: In order to identify as many prospective tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Persu, Cristian, Braschi, Emmanuel, Lavelle, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Polish Urological Association 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165668/
https://www.ncbi.nlm.nih.gov/pubmed/25247085
http://dx.doi.org/10.5173/ceju.2014.03.art11
_version_ 1782335132077654016
author Persu, Cristian
Braschi, Emmanuel
Lavelle, John
author_facet Persu, Cristian
Braschi, Emmanuel
Lavelle, John
author_sort Persu, Cristian
collection PubMed
description INTRODUCTION: The neurogenic urinary bladder is defined as a dysfunctional bladder associated with a known neurological injury. We review the data from good quality clinical trials looking at drug therapy for the neurogenic bladder. MATERIALS AND METHODS: In order to identify as many prospective trials as possible, we performed Internet searches, using the same search string: Urinary Bladder, neurogenic (MESH). In each case, the search was limited to clinical trial, prospective trial, subjects were human and the language was English. There was no year limit for our search. The next step was duplicate removal, which led to a final number of 580 papers. We defined clear inclusion criteria for the papers. RESULTS: A total of 82 full text papers were reviewed and analyzed according to the previously mentioned algorithm. The oldest two prospective clinical trials date back to 1976, with an obvious increase in number of trials each year, reaching more than five trials per year after 2001, which demonstrates increased interest toward the subject. The total number of patients included in the trials is 3904, 888 of which are children. The male: female ratio is close to 1, although there were 9 studies where no information regarding the sex of the patients was available. CONCLUSIONS: Our analysis stresses the acute need for good quality trials looking at the drugs used for the management of the patients with neurogenic bladders, with adequate statistical power to support the data they present.
format Online
Article
Text
id pubmed-4165668
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Polish Urological Association
record_format MEDLINE/PubMed
spelling pubmed-41656682014-09-22 A review of prospective Clinical Trials for neurogenic bladder: Pharmaceuticals Persu, Cristian Braschi, Emmanuel Lavelle, John Cent European J Urol Review Paper INTRODUCTION: The neurogenic urinary bladder is defined as a dysfunctional bladder associated with a known neurological injury. We review the data from good quality clinical trials looking at drug therapy for the neurogenic bladder. MATERIALS AND METHODS: In order to identify as many prospective trials as possible, we performed Internet searches, using the same search string: Urinary Bladder, neurogenic (MESH). In each case, the search was limited to clinical trial, prospective trial, subjects were human and the language was English. There was no year limit for our search. The next step was duplicate removal, which led to a final number of 580 papers. We defined clear inclusion criteria for the papers. RESULTS: A total of 82 full text papers were reviewed and analyzed according to the previously mentioned algorithm. The oldest two prospective clinical trials date back to 1976, with an obvious increase in number of trials each year, reaching more than five trials per year after 2001, which demonstrates increased interest toward the subject. The total number of patients included in the trials is 3904, 888 of which are children. The male: female ratio is close to 1, although there were 9 studies where no information regarding the sex of the patients was available. CONCLUSIONS: Our analysis stresses the acute need for good quality trials looking at the drugs used for the management of the patients with neurogenic bladders, with adequate statistical power to support the data they present. Polish Urological Association 2014-08-18 2014 /pmc/articles/PMC4165668/ /pubmed/25247085 http://dx.doi.org/10.5173/ceju.2014.03.art11 Text en Copyright by Polish Urological Association http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Paper
Persu, Cristian
Braschi, Emmanuel
Lavelle, John
A review of prospective Clinical Trials for neurogenic bladder: Pharmaceuticals
title A review of prospective Clinical Trials for neurogenic bladder: Pharmaceuticals
title_full A review of prospective Clinical Trials for neurogenic bladder: Pharmaceuticals
title_fullStr A review of prospective Clinical Trials for neurogenic bladder: Pharmaceuticals
title_full_unstemmed A review of prospective Clinical Trials for neurogenic bladder: Pharmaceuticals
title_short A review of prospective Clinical Trials for neurogenic bladder: Pharmaceuticals
title_sort review of prospective clinical trials for neurogenic bladder: pharmaceuticals
topic Review Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165668/
https://www.ncbi.nlm.nih.gov/pubmed/25247085
http://dx.doi.org/10.5173/ceju.2014.03.art11
work_keys_str_mv AT persucristian areviewofprospectiveclinicaltrialsforneurogenicbladderpharmaceuticals
AT braschiemmanuel areviewofprospectiveclinicaltrialsforneurogenicbladderpharmaceuticals
AT lavellejohn areviewofprospectiveclinicaltrialsforneurogenicbladderpharmaceuticals
AT persucristian reviewofprospectiveclinicaltrialsforneurogenicbladderpharmaceuticals
AT braschiemmanuel reviewofprospectiveclinicaltrialsforneurogenicbladderpharmaceuticals
AT lavellejohn reviewofprospectiveclinicaltrialsforneurogenicbladderpharmaceuticals